valproic acid has been researched along with sirolimus in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 18 (78.26) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Cuddon, P; Fleming, A; Floto, RA; Goldsmith, P; Jahreiss, L; O'Kane, CJ; Pask, D; Rubinsztein, DC; Saiki, S; Sarkar, S; Siddiqi, FH; Ttofi, EK; Williams, A | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
| Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Seibel, JM; Tsaur, I; Wedel, S; Wiesner, C | 1 |
| Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Makarević, J; Seibel, JM; Tsaur, I; Wedel, S; Wiesner, C | 1 |
| Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Makarević, J; Seibel, JM; Tsaur, I; Waaga-Gasser, A; Wedel, S | 1 |
| Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V | 1 |
| Bartsch, G; Blaheta, RA; Dauselt, A; Haferkamp, A; Juengel, E; Makarević, J; Tsaur, I; Wiesner, C | 1 |
| Brehm, R; Bremmer, F; Krahn, L; Loertzer, H; Strauss, A; Thelen, P | 1 |
| Blatt, J; Bridges, AS; Coulter, DW; Davis, IJ; Deal, AM; Khan, WA; McFadden, A; Moats-Staats, BM; Oesterheld, J; Patel, J; Smith, SV; Walko, C | 1 |
| Chen, SJ; Cheng, S; Dong, LH; Shen, Y; Shen, ZX; Wang, L; Zhao, WL; Zheng, Z | 1 |
| Cheng, S; Dong, LH; Wang, L; Zhao, WL; Zhao, Y; Zheng, Z | 1 |
| Bartsch, G; Blaheta, RA; Haferkamp, A; Harder, S; Juengel, E; Makarevi, J; Mani, J; Natsheh, I; Nelson, K; Nowaz, S; Reiter, M; Tsaur, I; Werner, I | 1 |
| Lin, F; Qin, ZH | 1 |
| Fuentes, JM; Gómez-Sánchez, R; González-Polo, RA; Pedro, JM; Pizarro-Estrella, E; Rodríguez-Arribas, M; Yakhine-Diop, SM | 1 |
| Aguirre, GD; Clark, E; Gamm, DM; Guziewicz, KE; Kuai, D; Lu, J; Meyer, J; Singh, R; Smith, M; Verhoeven, A; Wilson, M | 1 |
| Cheng, S; Janin, A; Ji, MM; Liu, H; Shen, Y; Wang, L; Xu, PP; Xue, W; Zhan, Q; Zhao, WL; Zhao, X; Zhao, Y | 1 |
| Hagino, Y; Ikeda, K; Kashii, H; Kobayashi, T; Kotajima-Murakami, H; Nishito, Y; Sato, A; Takamatsu, Y; Tanaka, M; Uchino, S | 1 |
| Fischer, M; Fleischmann, M; Fortner, C; Heidel, FH; Hochhaus, A; Kirkpatrick, J; Schnetzke, U; Scholl, S | 1 |
| Costa, A; Curti, L; D'Ambrosio, M; Gerace, E; Iezzi, D; Ilari, A; La Rocca, A; Luceri, C; Mannaioni, G; Masi, A; Ranieri, G; Scardigli, M; Silvestri, L | 1 |
3 review(s) available for valproic acid and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment?
Topics: Autophagy; Carbamazepine; Humans; Huntingtin Protein; Huntington Disease; Lithium; Mutant Proteins; Nerve Tissue Proteins; Oxazoles; Peptides; Rilmenidine; Sirolimus; Trehalose; Trinucleotide Repeat Expansion; Valproic Acid | 2013 |
Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Topics: Animals; Autophagy; Disease Models, Animal; Food; Humans; Isothiocyanates; Lithium; Neurodegenerative Diseases; Resveratrol; Sirolimus; Spermidine; Stilbenes; Sulfoxides; Trehalose; Valproic Acid | 2015 |
2 trial(s) available for valproic acid and sirolimus
| Article | Year |
|---|---|
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Diphenhydramine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Early Termination of Clinical Trials; Fatigue; Female; Hematologic Diseases; Histone Deacetylase Inhibitors; Humans; Infusions, Intravenous; Male; Mucositis; Neoplasms; Pain; Sirolimus; Valproic Acid | 2013 |
18 other study(ies) available for valproic acid and sirolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
Topics: Animals; Autophagy; Calcium Channels, L-Type; Clonidine; Cyclic AMP; Humans; Huntington Disease; Imidazoline Receptors; Minoxidil; Protein Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Type C Phospholipases; Verapamil | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Movement; Cell Survival; Drug Screening Assays, Antitumor; Drug Therapy, Combination; ErbB Receptors; Everolimus; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Valproic Acid | 2011 |
Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Topics: Cell Adhesion; Cell Movement; Drug Therapy, Combination; Enzyme Inhibitors; Everolimus; Histone Deacetylases; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Sirolimus; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Valproic Acid | 2011 |
Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinases; Cyclins; Down-Regulation; Everolimus; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Purines; Signal Transduction; Sirolimus; Valproic Acid | 2011 |
Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells.
Topics: Acetylation; Apoptosis; Carcinoma, Renal Cell; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Everolimus; Histone Deacetylase Inhibitors; Histones; Humans; Kidney Neoplasms; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Sirolimus; TOR Serine-Threonine Kinases; Valproic Acid | 2012 |
Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Nude; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Valproic Acid | 2013 |
Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Burkitt Lymphoma; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Mice; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
[Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
Topics: Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Histone Deacetylase 1; Histone Deacetylases; Humans; Lymphoma, Large B-Cell, Diffuse; Microtubule-Associated Proteins; Sirolimus; Valproic Acid | 2013 |
HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cyclin A; Cyclin-Dependent Kinase 2; Drug Resistance, Neoplasm; Everolimus; G2 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Sirolimus; Valproic Acid | 2014 |
Pharmacological Modulation of Photoreceptor Outer Segment Degradation in a Human iPS Cell Model of Inherited Macular Degeneration.
Topics: Animals; Autophagy; Cells, Cultured; Disease Models, Animal; Dogs; Enzyme Inhibitors; Humans; Induced Pluripotent Stem Cells; Macrolides; Models, Biological; Oxidation-Reduction; Primary Cell Culture; Proteolysis; Retinal Photoreceptor Cell Outer Segment; Retinal Pigment Epithelium; Sirolimus; Valproic Acid; Vitelliform Macular Dystrophy | 2015 |
Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Humans; Inositol 1,4,5-Trisphosphate; Lymphoma; Mitochondria; Signal Transduction; Sirolimus; Valproic Acid | 2015 |
Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero.
Topics: Animals; Body Weight; Female; Gene Expression Regulation, Developmental; Gene Regulatory Networks; Interpersonal Relations; Mice, Inbred C57BL; Motor Activity; Phosphorylation; Pregnancy; Prenatal Exposure Delayed Effects; Ribosomal Protein S6; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Valproic Acid | 2019 |
Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Mice; Mutant Proteins; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; Tunicamycin; Valproic Acid | 2021 |
Acute rapamycin rescues the hyperexcitable phenotype of accumbal medium spiny neurons in the valproic acid rat model of autism spectrum disorder.
Topics: Animals; Autism Spectrum Disorder; Behavior, Animal; Disease Models, Animal; Female; Male; Neurons; Phenotype; Potassium; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Sirolimus; TOR Serine-Threonine Kinases; Valproic Acid | 2022 |